Burn News and Research

RSS

Study examines potential health benefits of DCT

Imagine your delight while enjoying your favorite Mexican food - perhaps a fully loaded bean burrito topped with an ample supply of thinly sliced jalepeño peppers. What happens when you bite into a few more peppers than you bargained for? Does this thought conjure up the thought of a little heat? Perhaps even a bit of sweat on the brow? Indeed, food scientists can tell you that hot peppers contain a substance called capsaicin that not only adds spice to our foods but can actually cause your body to heat up.

28 Apr 2010

Loyola University Health System to appreciate volunteers for making hats, blankets for cancer patients

In a special blessing ceremony Loyola University Health System will say "thank you" to volunteers from local parishes who have donated their time and talents to make comfort items such as hats and blankets for cancer patients at the Cardinal Bernardin Cancer Center.

28 Apr 2010

CTI receives positive reception from EMEA clinical experts for pixantrone MAA

Cell Therapeutics, Inc. today reported recent accomplishments and financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Pepscan reaches partnering agreement for therapeutic vaccine portfolio with Immunovo

Pepscan, the Netherlands based biotechnology firm focusing on protein mimicking technology for the generation of immune therapeutics, today announced that it reached a partnering agreement for its therapeutic vaccine portfolio with Immunovo BV of 's-Hertogenbosch. Under the terms of the agreement Pepscan will receive an undisclosed cash payment as well as a minority interest in Immunovo.

28 Apr 2010

NCCTG to conduct Phase II study of brostallicin in combination with cisplatin for mTNBC cancer

Cell Therapeutics, Inc. today announced that the North Central Cancer Treatment Group ("NCCTG") plans to conduct a Phase II study of brostallicin in combination with cisplatin in patients with metastatic triple-negative breast ("mTNBC") cancer, defined by tumors lacking expression of estrogen, progesterone receptors and without over-expression of HER2. Additionally, the majority of breast cancers that are associated with the susceptibility mutation (BRCA1) are of the triple-negative type.

28 Apr 2010

Discovery Labs reports first-quarter results, updates on Surfaxin and key pipeline programs

Discovery Laboratories, Inc., a biotechnology company developing its novel synthetic surfactant and aerosol technologies for respiratory diseases, today provides an update on Surfaxin® and key pipeline and business initiatives and reports financial results for the first quarter ended March 31, 2010.

28 Apr 2010

Study analyzes effects of untimely and sudden parental death on childhood development

Losing a parent to suicide makes children more likely to die by suicide themselves and increases their risk of developing a range of major psychiatric disorders, according to a study led by Johns Hopkins Children's Center that is believed to be the largest one to date on the subject.

22 Apr 2010

Access Pharmaceuticals to present MuGard clinical data at 2010 MASCC conference

ACCESS PHARMACEUTICALS, INC., a biopharmaceutical company specializing in products for cancer and supportive care, announced today that it will present data from the ongoing work involving its lead product, MuGard, and host an oral mucositis symposium at the MASCC conference being held in Vancouver, B.C. on June 24-26, 2010. MuGard is Access Pharma's FDA-approved product for the management of oral mucositis, a debilitating side effect of many anticancer treatments.

22 Apr 2010

Homeopathy – Is it a safer and effective alternative?

Studies have shown that nearly 45% Britons rely on Homeopathy, a branch of medicine that has been doubted by many and loved by an equal number.

20 Apr 2010

CombiMatrix announces operational restructuring plan

CombiMatrix Corporation announced today that it is implementing a restructuring plan to significantly reduce operating costs, increase the focus on the Company's diagnostic services business and transition senior management. After the restructuring, CombiMatrix will be focused on its diagnostics services business, including increasing utilization of its existing tests, expanding the test menu, increasing the number of customers and partners, and improving reimbursement for its testing services.

20 Apr 2010

HEALTHPOINT provides donation to support 100 free AAWC patient memberships

HEALTHPOINT today announced it will provide a donation to the Association for the Advancement of Wound Care Patient Advocacy Campaign to support 100 free AAWC patient memberships. The AAWC initiative is to be formally launched today during the Opening Ceremony of the Spring 2010 Symposium on Advanced Wound Care, on April 17, 2010, from 2:15-3:00 PM at the Gaylord Palms Hotel and Convention Center in Orlando, FL.

19 Apr 2010

Data on ConvaTec's medical devices to be presented at SAWC/WHS 2010

ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, today announced that data related to several of its medical devices will be presented at the 23rd Annual Symposium on Advanced Wound Care and Wound Healing Society in Orlando, Florida from April 17th to April 20th, 2010.

19 Apr 2010

USW calls for greater attention to process safety within refining sector

The United Steelworkers said today that Wednesday's fire at ExxonMobil's Baton Rouge, La., refinery that injured one employee and two contractors demonstrates the urgency of the union's call for greater attention to process safety within the refining sector. This incident follows less than two weeks after the deadly Tesoro refinery explosion in Anacortes, Wash.

17 Apr 2010

Immune system cells that impede wound-healing process discovered

A new discovery about the wound-healing process could lead to better treatments for diabetics and other patients who have wounds that are slow to heal.

17 Apr 2010

Repligen expects total revenue of $21.0M for fiscal year 2010

Repligen Corporation today announced preliminary financial results for fiscal year 2010 which ended March 31, 2010. Total revenue for the year is expected to be $21.0 million, including $10.3 million of bioprocessing product revenue and $10.7 million of royalty and other revenue. Research and development expenses are expected to be between $13.8-$14.2 million and selling, general and administrative expenses between $6.8-$7.2 million.

16 Apr 2010

Cell Therapeutics reduces workforce to cut operating costs

Cell Therapeutics, Inc. today announced it has conducted an immediate reduction in force of 36 employees. The Company expects the reduction in force and elimination of previously planned increase in commercial personnel along with a reduction in planned operating expenses to result in savings of approximately $16 million in 2010.

15 Apr 2010

BeaconEquity.com releases investment report featuring Antigenics

BeaconEquity.com announces an investment report featuring Antigenics Inc. The report includes financial, comparative and investment analyses, and pertinent industry information you need to know to make an educated investment decision.

15 Apr 2010

Use of silver dressing in burn cases questioned

The use of expensive silver dressing in burn cases is being brought under the scanner by an editorial in the Drug and Therapeutics Bulletin. The NHS has increased its spending from £23 million in 2005 to around £25 million in 2006/7 on such products. The author asks if expensive silver dressing is really justified when cheaper alternatives are available.

15 Apr 2010

Silence Therapeutics reorganizes resources following Intradigm merger

Silence Therapeutics plc announces that the Company is executing a strategic plan designed to optimally organize its resources following its recent merger with Intradigm Corporation. Moving forward, all research activities related to Silence's novel RNA interference (RNAi) therapeutic platforms, including technologies that have emerged from both Silence and Intradigm, will take place at the Company's Berlin location.

13 Apr 2010

CSL Behring calls for grant requests through LEAD program

CSL Behring, a global leader in the plasma protein biotherapeutics industry, is calling for grant requests through its Local Empowerment for Advocacy Development program. The LEAD program awards funds to United States patient organizations that assist people with rare diseases in advocating for continued access to health care and life-saving plasma protein therapies.

13 Apr 2010